Ocular Therapeutix joins Baird Global Healthcare Conference fireside chatPUBT·Sep 1 at 11:04 AMOCUL0.00%
The Structural Opportunity of Niche Assets: Value Chain Reconfiguration Beyond the AggregatorsGlobal Report·Sep 1 at 10:13 AMCPNG-1.42%INDI+3.75%
Niche Equities Show Divergent Q2 2026 Results Amid Market ShiftsGlobal Report·Aug 25 at 10:12 AMWU-0.97%OCUL0.00%
Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story BuildsSimplywall·Aug 25 at 05:26 AMOCUL0.00%
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by AnalystsMarket Beat·Aug 22 at 06:44 AMOCUL0.00%
Why Is Ocular Therapeutix Stock Gaining Monday?benzinga_article·Aug 17 at 05:48 PMOCUL0.00%EYPT+0.33%
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead AssetTip Ranks·Aug 17 at 03:35 PMOCUL0.00%
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Mondaybenzinga_article·Aug 17 at 01:51 PMMESO+1.05%SMTC+9.22%
Ocular Therapeutix grants new SVP Beth Rada options for 85,000 shares, 28,000 RSUs under inducement planPUBT·Aug 13 at 08:19 PMOCUL0.00%
The Market's Junk Drawer: Sifting Through AI Hypes, Biotech Bets, and Failing TractorsGlobal Report·Aug 11 at 10:12 AMSBGSY+0.27%PHM+0.11%
Ocular Therapeutix grants inducement awards to new hires, including options priced at $8.4 per sharePUBT·Aug 7 at 08:05 PMOCUL0.00%
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading PracticesTip Ranks·Aug 4 at 06:00 AMOCUL0.00%
Ocular Therapeutix Q2 FY26 net loss widens to $78.76 million; revenue rises 0.12% to $13.48 millionPUBT·Aug 3 at 11:02 AMOCUL0.00%
